a pilot study evaluated intravenous methotrexate ( mtx ) ( initial dose 40 mg/m2 ; final dose , 26 mg/m2 ) , weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral mtx .
C0003873
rheumatoid
C0025677
mtx